16-1220649-C-T
Variant names:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_021098.3(CACNA1H):c.6717C>T(p.Gly2239Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00175 in 1,603,900 control chromosomes in the GnomAD database, including 9 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0017 ( 9 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.206
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.72).
BP6
Variant 16-1220649-C-T is Benign according to our data. Variant chr16-1220649-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 460175.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-1220649-C-T is described in Lovd as [Likely_benign].
BP7
Synonymous conserved (PhyloP=-0.206 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00203 (308/152048) while in subpopulation AFR AF= 0.0027 (112/41494). AF 95% confidence interval is 0.00229. There are 0 homozygotes in gnomad4. There are 143 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High AC in GnomAd4 at 308 AD gene.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1H | ENST00000348261.11 | c.6717C>T | p.Gly2239Gly | synonymous_variant | Exon 35 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
CACNA1H | ENST00000565831.6 | c.6699C>T | p.Gly2233Gly | synonymous_variant | Exon 33 of 33 | 1 | ENSP00000455840.1 | |||
CACNA1H | ENST00000638323.1 | c.6678C>T | p.Gly2226Gly | synonymous_variant | Exon 35 of 35 | 5 | ENSP00000492267.1 | |||
CACNA1H | ENST00000569107.5 | c.2955C>T | p.Gly985Gly | synonymous_variant | Exon 17 of 17 | 1 | ENSP00000454990.2 | |||
CACNA1H | ENST00000564231.5 | c.2907C>T | p.Gly969Gly | synonymous_variant | Exon 18 of 18 | 1 | ENSP00000457555.2 | |||
CACNA1H | ENST00000562079.5 | c.2889C>T | p.Gly963Gly | synonymous_variant | Exon 17 of 17 | 1 | ENSP00000454581.2 | |||
CACNA1H | ENST00000639478.1 | n.*1765C>T | non_coding_transcript_exon_variant | Exon 35 of 35 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000640028.1 | n.*4535C>T | non_coding_transcript_exon_variant | Exon 35 of 35 | 5 | ENSP00000491488.1 | ||||
CACNA1H | ENST00000639478.1 | n.*1765C>T | 3_prime_UTR_variant | Exon 35 of 35 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000640028.1 | n.*4535C>T | 3_prime_UTR_variant | Exon 35 of 35 | 5 | ENSP00000491488.1 |
Frequencies
GnomAD3 genomes AF: 0.00202 AC: 307AN: 151930Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
307
AN:
151930
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00120 AC: 268AN: 223490Hom.: 0 AF XY: 0.00122 AC XY: 151AN XY: 123648
GnomAD3 exomes
AF:
AC:
268
AN:
223490
Hom.:
AF XY:
AC XY:
151
AN XY:
123648
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00172 AC: 2495AN: 1451852Hom.: 9 Cov.: 35 AF XY: 0.00168 AC XY: 1215AN XY: 721612
GnomAD4 exome
AF:
AC:
2495
AN:
1451852
Hom.:
Cov.:
35
AF XY:
AC XY:
1215
AN XY:
721612
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00203 AC: 308AN: 152048Hom.: 0 Cov.: 32 AF XY: 0.00192 AC XY: 143AN XY: 74320
GnomAD4 genome
AF:
AC:
308
AN:
152048
Hom.:
Cov.:
32
AF XY:
AC XY:
143
AN XY:
74320
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
5
AN:
3478
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Mar 26, 2019
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Feb 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
CACNA1H: BP4, BP7 -
not specified Benign:1
Mar 04, 2025
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at